ArriVent BioPharma, Inc. AVBP Business Segments
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Research And Development Expense Product With Specified Ingredient by Product | ||||||
| Drug Firmonertinib Favour | $331K+16,450% | $65K-53.2% | $259K+151% | $71K+294% | $2K-83.3% | |
| Drug Firmonertinib Further | $1.74M-33.0% | $2.28M+24.6% | $2.12M-31.9% | $2.85M-27.1% | $2.6M-24.2% | |
| Drug Firmonertinib Furvent | $9.13M-3.3% | $15.69M+58.9% | $13.82M+54.2% | $9.79M+39.9% | $9.45M+13.7% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does ArriVent BioPharma, Inc. break its business down?
- ArriVent BioPharma, Inc. (AVBP) reports research and development expense product with specified ingredient by product across 3 parts — Drug Firmonertinib Favour, Drug Firmonertinib Further and Drug Firmonertinib Furvent. Each is extracted from the segment footnotes and tracked over time.
- Where does ArriVent BioPharma, Inc.'s segment data come from?
- Segment breakdowns are pulled from the segment footnotes in ArriVent BioPharma, Inc.'s SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.